ARE logo

ARE

Alexandria Real Estate Equities Inc.

$48.37
+$0.52(+1.09%)
52
Overall
80
Value
33
Tech
44
Quality
How is this score calculated?
Market Cap
$7.77B
Volume
1.39M
52W Range
$39.41 - $88.24
Target Price
$51.93

Company Overview

Mkt Cap$7.77BPrice$48.37
Volume1.39MChange+1.09%
P/E Ratio-5.4Open$47.94
Revenue$3.0BPrev Close$47.85
Net Income$-1.4B52W Range$39.41 - $88.24
Div Yield2.88%Target$51.93
Overall52Value80
Quality44Technical33

No chart data available

About Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Sector: Real Estate
Industry: REIT - Office

Latest News

Ultragenyx Pharmaceutical (RARE) Receives a Buy from J.P. Morgan

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $72.00. T...

TipRanks Auto-Generated Intelligence Newsdesk2 days ago

Mare Group Increases Treasury Share Holdings Under Ongoing Buyback Programme

TipRanks Italy Auto-Generated Newsdesk3 days ago

Daré Bioscience Nears First Revenues Amid Cash Squeeze

TipRanks Auto-Generated Newsdesk6 days ago

Ultragenyx Earnings Call Balances Growth and Cash Burn

TipRanks Auto-Generated Newsdesk6 days ago

Daré Bioscience Completes Regulation A Investor Unit Offering

TipRanks Auto-Generated Newsdesk7 days ago
ABCD
1SymbolPriceChangeVol
2ARE$48.37+1.1%1.39M
3
4
5
6

Get Alexandria Real Estate Equities Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.